Glioma is the most common central nervous system primary tumor,accounting for about 40%of intracranial tumors.In recent years,studies have shown that the human brain is not immune-free zone.The low immunogenicity of t...Glioma is the most common central nervous system primary tumor,accounting for about 40%of intracranial tumors.In recent years,studies have shown that the human brain is not immune-free zone.The low immunogenicity of the tumor itself,tumor-generated immunosuppressive factors,and the low immunity of tumor patients all contribute to the“immune escape”phenomenon of glioma cells.Dendritic cells(DCs),as the strongest antigen-presenting cells in the body,play an important role in tumor immunotherapy with T-cell recognizing tumor antigens as the core.Therefore,it is necessary to adopt a strategy of culturing and sensitizing DC cells in vitro to increase their number and improve their function before returning to the body for treatment of patients with glioma.展开更多
Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations.The fifth edition of the WHO Classification of Tumors of the Central Nervous System...Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations.The fifth edition of the WHO Classification of Tumors of the Central Nervous System(WHO CNS5),published in 2021,introduces major changes that advance the role of molecular diagnostics in meningiomas.To follow the revision of WHO CNS5,this expert consensus statement was formed jointly by the Group of Neuro-Oncology,Society of Neurosurgery,Chinese Medical Association together with neuropathologists and evidence-based experts.The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.展开更多
文摘Glioma is the most common central nervous system primary tumor,accounting for about 40%of intracranial tumors.In recent years,studies have shown that the human brain is not immune-free zone.The low immunogenicity of the tumor itself,tumor-generated immunosuppressive factors,and the low immunity of tumor patients all contribute to the“immune escape”phenomenon of glioma cells.Dendritic cells(DCs),as the strongest antigen-presenting cells in the body,play an important role in tumor immunotherapy with T-cell recognizing tumor antigens as the core.Therefore,it is necessary to adopt a strategy of culturing and sensitizing DC cells in vitro to increase their number and improve their function before returning to the body for treatment of patients with glioma.
文摘Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations.The fifth edition of the WHO Classification of Tumors of the Central Nervous System(WHO CNS5),published in 2021,introduces major changes that advance the role of molecular diagnostics in meningiomas.To follow the revision of WHO CNS5,this expert consensus statement was formed jointly by the Group of Neuro-Oncology,Society of Neurosurgery,Chinese Medical Association together with neuropathologists and evidence-based experts.The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.